NAGE Q3 2023 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+14.3% YoY

Gross Profit

$12M61.4% margin

Operating Income

-$1M-5.9% margin

Net Income

-$959,000-4.9% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-4.1%

Cash Flow

Operating Cash Flow

$396,000

Free Cash Flow

$370,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$53M

Total Liabilities

$26M

Stockholders' Equity

$27M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$17M	+14.3%
Gross Profit	$12M	$10M	+17.3%
Operating Income	-$1M	-$3M	+62.6%
Net Income	-$959,000	-$985,000	+2.6%